111 related articles for article (PubMed ID: 15961085)
1. Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists.
Pastorin G; Bolcato C; Cacciari B; Kachler S; Klotz KN; Montopoli C; Moro S; Spalluto G
Farmaco; 2005 Aug; 60(8):643-51. PubMed ID: 15961085
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists.
Pastorin G; Bolcato C; Cacciari B; Kachler S; Klotz KN; Montopoli C; Moro S; Spalluto G
Farmaco; 2005 Apr; 60(4):299-306. PubMed ID: 15848204
[TBL] [Abstract][Full Text] [Related]
3. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.
Carotti A; Cadavid MI; Centeno NB; Esteve C; Loza MI; Martinez A; Nieto R; Raviña E; Sanz F; Segarra V; Sotelo E; Stefanachi A; Vidal B
J Med Chem; 2006 Jan; 49(1):282-99. PubMed ID: 16392813
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
7. 1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.
Fernández F; Caamaño O; Isabel Nieto M; López C; García-Mera X; Stefanachi A; Nicolotti O; Isabel Loza M; Brea J; Esteve C; Segarra V; Vidal B; Carotti A
Bioorg Med Chem; 2009 May; 17(10):3618-29. PubMed ID: 19398343
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pharmacological evaluation of novel 1,3,8- and 1,3,7,8-substituted xanthines as adenosine receptor antagonists.
Rodríguez-Borges JE; García-Mera X; Balo MC; Brea J; Caamaño O; Fernández F; López C; Loza MI; Nieto MI
Bioorg Med Chem; 2010 Mar; 18(5):2001-9. PubMed ID: 20137957
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological assays and QSAR studies of N-(9-benzyl-2-phenyl-8-azapurin-6-yl)-amides as ligands for A1 adenosine receptors.
Giorgi I; Leonardi M; Pietra D; Biagi G; Borghini A; Massarelli I; Ciampi O; Bianucci AM
Bioorg Med Chem; 2009 Mar; 17(5):1817-30. PubMed ID: 19230680
[TBL] [Abstract][Full Text] [Related]
10. 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists.
Chang LC; Spanjersberg RF; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Brussee J; Ijzerman AP
J Med Chem; 2006 May; 49(10):2861-7. PubMed ID: 16686529
[TBL] [Abstract][Full Text] [Related]
11. Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.
Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Giles PR; Jordan AM; Knight AR; Lawrence A; Lerpiniere J; Misra A; Pratt RM; Todd RS; Upton R; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2920-3. PubMed ID: 18407496
[TBL] [Abstract][Full Text] [Related]
12. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacological evaluation of novel 1- and 8-substituted-3-furfuryl xanthines as adenosine receptor antagonists.
Balo MC; Brea J; Caamaño O; Fernández F; García-Mera X; López C; Loza MI; Nieto MI; Rodríguez-Borges JE
Bioorg Med Chem; 2009 Sep; 17(18):6755-60. PubMed ID: 19682912
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
15. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Minetti P; Tinti MO; Carminati P; Castorina M; Di Cesare MA; Di Serio S; Gallo G; Ghirardi O; Giorgi F; Giorgi L; Piersanti G; Bartoccini F; Tarzia G
J Med Chem; 2005 Nov; 48(22):6887-96. PubMed ID: 16250647
[TBL] [Abstract][Full Text] [Related]
16. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Preti D; Tabrizi MA; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Merighi S; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(14):4697-701. PubMed ID: 16000006
[TBL] [Abstract][Full Text] [Related]
17. Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands.
Drabczyńska A; Müller CE; Schiedel A; Schumacher B; Karolak-Wojciechowska J; Fruziński A; Zobnina W; Yuzlenko O; Kieć-Kononowicz K
Bioorg Med Chem; 2007 Nov; 15(22):6956-74. PubMed ID: 17827019
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
19. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.
Roy K; Leonard JT; Sengupta C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3705-9. PubMed ID: 15203147
[TBL] [Abstract][Full Text] [Related]
20. 1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor.
Stefanachi A; Brea JM; Cadavid MI; Centeno NB; Esteve C; Loza MI; Martinez A; Nieto R; Raviña E; Sanz F; Segarra V; Sotelo E; Vidal B; Carotti A
Bioorg Med Chem; 2008 Mar; 16(6):2852-69. PubMed ID: 18226909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
